Study on linear growth and thyroid function for 12 years in patients with β thalassemia major

Soliman, Ashraf; Al, Yafei Fawzia; Al-Naimi, Lolwa; Al-Marri, Noora; Sabt, Aml; Yassun, Mohamed; Desanctis, Vincenzo

doi:10.1530/endoabs.32.p992

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study showed that progressive of thyroid dysfunction observed about 35% of β-thalassemia patients who have the age 18.The lack of elevated of TSH in response to low levels of T4 in these patients was indicated a high incidence of defective pituitary thyrotrophic function (Soliman et al, 2013). However, the variation of prevalence may be related to the age of study population, duration of blood transfusions, ferritin levels and dose of the iron-chelating agent (Aydinok et al, 2002;Zervas et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…The frequency of hypothyroidism in β-thalassemia patients changes between 6 to 30% in the different countries depending on chelation regimens (Sanctis, et al, 2004). Thyroid dysfunction was defined on the following: overt hypothyroidism (low free thyroxine [FT4] and increased thyroid-stimulating hormone levels >5µIU/ml); subclinical hypothyroidism (normal level to theFT4 and TSH between 5-10 µIU/ml) and central hypothyroidism (low FT4 and normal or decreased TSH (Soliman et al, 2013). All studies have confirmed that the prevalence of hypogonadism in the adult β-thalassemia patients is very high (Tiosano and Hochberg, 2001;Merchant et al, 2011;Sharaf et al,2014).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Study of the Endocrine Disorders of Βeta-Thalassemia Major Patients and Control Group in Duhok Province

Ali

Jubrial

Najeeb

2018

SJUOZ

View full text Add to dashboard Cite

Beta- thalassemia major is a type of inherited blood disorder, characterized by impaired synthesis of the beta chains. Currently, blood transfusion and sufficient iron chelation therapy are important for treatment and follow up of thalassemia patients. Unfortunately, repeated blood transfusion causes the progressive iron overload. Consequently, the excess iron is deposited as hemosiderin and ferritin in the tissues and multiple endocrine complications. In comparison with healthy control group, the results indicated significant (p<0.05) increased TSH level (3.86 ± 2.7 1µIU/ml), whereas the serum level of T4 hormone did not significantly differ between the two groups. In the thalassemia patients, 23.68% (9/38) had subclinical hypothyroidism. The mean level of estradiol in patients (30.60± 14.68pg/ml) is high significant (p< 0.01) decreased that compared with the control persons (13.83 ± 9.06 pg/ml) more than 13 years. Testosterone level in patients was significantly different (P< 0.001) respectively from the control group. The mean of testosterone level was 1.22± 0.83 ng/ml in thalassemia patients and 3.71± 1.32ng/ml in control group more than 14 years. These results indicate high prevalence hypothyroidism and puberty defection. Endocrine drugs supplementation is a safe for patients which have each type of endocrine disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparative Study of the Endocrine Disorders of Βeta-Thalassemia Major Patients and Control Group in Duhok Province

Ali

Jubrial

Najeeb

2018

SJUOZ

View full text Add to dashboard Cite

show abstract

“…Progressive worsening of thyroid function is observed in 35% of thalassemic patients by the age of 18 years. [ 68 ]…”

Section: Introductionmentioning

confidence: 99%

Insulin-like growth factor- I and factors affecting it in thalassemia major

Soliman¹,

Sanctis²,

Elalaily

et al. 2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Despite improvement of blood transfusion regimens and iron chelation therapy growth and maturational delay, cardiomyopathy, endocrinopathies and osteoporosis still occur in good number of thalassemic patients. Decreased IGF-1 secretion occurs in the majority of the thalassemic patients particularly those with growth and pubertal delay. Many factors contribute to this decreased synthesis of IGF-I including disturbed growth hormone (GH) - insulin-like growth factor - I (IGF-I) axis. The possible factors contributing to low IGF-I synthesis in thalassemia and the possible interaction between low IGF-I secretion and the occurrence of these complications is discussed in this mini-review. Improvement of IGF-I secretion in thalassemic patients should be intended to improve linear growth and bone mineral accretion in thalassemic patients. This can be attained through adequate correction of anemia and proper chelation, nutritional supplementation (increasing caloric intake), correction of vitamin D and zinc deficiencies, induction of puberty and correction of hypogonadism at the proper time and treating GH deficiency. This review paper provides a summary of the current state of knowledge regarding IGF-I and factors affecting it in patients with thalassaemia major (TM). Search on PubMed and reference lists of articles with the term ‘IGF-I, GH, growth, thalassemia, thyroxine, anemia, vitamin D, and zinc’ was carried out. A hundred and forty-eight articles were found and used in the write up and the data analyzed was included in this report.

show abstract

Study on linear growth and thyroid function for 12 years in patients with β thalassemia major

Cited by 2 publications

References 0 publications

Comparative Study of the Endocrine Disorders of Βeta-Thalassemia Major Patients and Control Group in Duhok Province

Comparative Study of the Endocrine Disorders of Βeta-Thalassemia Major Patients and Control Group in Duhok Province

Insulin-like growth factor- I and factors affecting it in thalassemia major

Contact Info

Product

Resources

About